Antagonistic relationship between Dpp and EGFR signaling in Drosophila head patterning.

Dev Biol

Department of Molecular Cell and Developmental Biology, University of California Los Angeles, Los Angeles, CA 90095, USA.

Published: November 2003

The Drosophila eye field that gives rise to the visual system and dorsal head epidermis forms an unpaired anlage located in the dorsal head ectoderm. The eye field expresses and requires both Dpp and EGFR signaling for its development. As shown in previous studies, EGFR is required for cell maintenance in the developing visual system. Dpp initially switches on the early eye genes so and eya in the eye field. Consecutively, high levels of Dpp in the dorsal midline inhibit these genes and promote development of head epidermis. We show that Dpp negatively regulates EGFR signaling, thereby increasing the amount of cell death in the dorsal midline. By this mechanism, Dpp controls the formation of a bilateral visual system and indirectly modulates cell death, which is essential for normal head morphogenesis. Loss of either Dpp or its downstream target, Zen, abolishes head epidermis fate and leads to the misexpression of dp-ERK in the dorsal midline. The resulting morphological phenotype consists of cyclopia, reduction of cell death, and failure of head involution. Ectopic expression of activated EGFR inhibits the Dpp target race and thereby causes cyclopia and defective head involution. We discuss possible mechanisms of Dpp and EGFR interaction in the embryo.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0012-1606(03)00448-2DOI Listing

Publication Analysis

Top Keywords

dpp egfr
12
egfr signaling
12
eye field
12
visual system
12
head epidermis
12
dorsal midline
12
cell death
12
dpp
9
head
8
dorsal head
8

Similar Publications

Background: To investigate the safety and efficiency of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetic kidney disease.

Methods: We conducted a comprehensive literature search across multiple databases, including Embase, PubMed, CNKI, and the Cochrane Central Register of Controlled Trials, from inception to January 2024. The search focused on randomized controlled trials (RCTs) that directly compared DPP-4 inhibitors with placebos or other glucose-lowering therapies.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare the kidney and heart health outcomes between two diabetes medications: DPP-4 inhibitors (DPP-4is) and SGLT-2 inhibitors (SGLT-2is) in patients with diabetic kidney disease (DKD).
  • Using Taiwan's health databases, researchers matched users of both medications and analyzed their effects on kidney and cardiovascular issues over two years.
  • Results showed that SGLT-2i users had significantly better outcomes, including lower risks of kidney failure and cardiovascular events, suggesting DPP-4is should be used less frequently in favor of SGLT-2is for adults with DKD.
View Article and Find Full Text PDF

Aim: To evaluate the renal prognosis of dipeptidyl peptidase-4 inhibitor (DPP-4i) users and non-users using real-world Asian data.

Methods: Using databases from DeSC Healthcare, Inc., patients aged 30 years or older who used antidiabetic drugs from 2014 to 2021 were identified.

View Article and Find Full Text PDF

Background/aim: Vildagliptin is one of the dipeptidyl peptidase-4 (DPP-4) inhibitors that have been shown to improve hyperglycemia in clinical trials among patients with type 2 diabetes. However, few studies have examined the efficacy of vildagliptin in patients with diabetic kidney disease (DKD).

Patients And Methods: Eight patients with DKD received oral vildagliptin 50-100 mg/day.

View Article and Find Full Text PDF

Aims: About 20-40% patients with type 2 diabetes mellitus (T2DM) had an increased risk of developing diabetic nephropathy (DN). Dipeptidyl peptidase-4 inhibitors (DPP-4i) were recommended for treatment of T2DM, while the impact of DPP-4i on renal function remained unclear. This study aimed to explore the effect of DPP-4i on renal parameter of estimated glomerular filtration rate (eGFR) and albumin-to-creatinine ratio (ACR) in T2DM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!